Stock Analysis
Qingdao Vland Biotech's (SHSE:603739) Anemic Earnings Might Be Worse Than You Think
Last week's earnings announcement from Qingdao Vland Biotech INC. (SHSE:603739) was disappointing to investors, with a sluggish profit figure. We did some further digging and think they have a few more reasons to be concerned beyond the statutory profit.
See our latest analysis for Qingdao Vland Biotech
The Impact Of Unusual Items On Profit
For anyone who wants to understand Qingdao Vland Biotech's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN„25m worth of unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And, after all, that's exactly what the accounting terminology implies. If Qingdao Vland Biotech doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
Our Take On Qingdao Vland Biotech's Profit Performance
Arguably, Qingdao Vland Biotech's statutory earnings have been distorted by unusual items boosting profit. Because of this, we think that it may be that Qingdao Vland Biotech's statutory profits are better than its underlying earnings power. Sadly, its EPS was down over the last twelve months. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. You'd be interested to know, that we found 2 warning signs for Qingdao Vland Biotech and you'll want to know about these bad boys.
Today we've zoomed in on a single data point to better understand the nature of Qingdao Vland Biotech's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
Valuation is complex, but we're here to simplify it.
Discover if Qingdao Vland Biotech might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SHSE:603739
Qingdao Vland Biotech
Engages in the research and development, production, and sale of enzyme preparations, microecological preparations, and animal health products in China and internationally.